Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.43 |
| ▸ | GCGR | P47871 | 5/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 3/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548615 | 0.77 | FFAR1 (0.36) | FFAR4FFAR1PTGS2CD274 | |
| SCHEMBL12880837 | 0.75 | MAPT (0.40) | GCGR | |
| SCHEMBL12865413 | 0.75 | FFAR1 (0.33) | FFAR4FFAR1 | |
| SCHEMBL17356573 | 0.74 | GCGR (0.36) | ALOX5GCGRRARBRARARARG | |
| SCHEMBL17356581 | 0.69 | GCGR (0.36) | ALOX5GCGRRARBRARARARG | |
| SCHEMBL21663934 | 0.67 | ALOX5 (0.43) | ALOX5RARBRARARARGPTGS2 | |
| SCHEMBL16258044 | 0.67 | RARB (0.53) | RARBRARARARGPTGS2 | |
| SCHEMBL17356649 | 0.66 | TYR (0.41) | ALOX5GCGRRARBRARARARG | |
| SCHEMBL17356622 | 0.66 | RARB (0.56) | RARBRARARARGPTGS2 | |
| SCHEMBL17356659 | 0.66 | RARB (0.49) | RARBRARARARGPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | NIPPON SODA CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034688-A1 | OPTICALLY ACTIVE DIBENZAZEPINE DERIVATIVES | DRD1, DRD4, DRD2 | ALOX5 2232/4885GCGR 2645/4885FFAR4 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.